SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders. To our Shareholders: Since my letter dated January 4, 2007, we have made significant progress in our mission to establish the industry for medical devices able to treat infectious disease. In this regard, I am pleased to inform you that researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR) have initiated studies of our Hemopurifier® as a potential treatment countermeasure against Category “A” bioterror threats, including Ebola, Marburg, and Lassa Hemorrhagic Fever.
